Treatment of individuals with NTRK fusion-positive cancers using first-generation TRK inhibitors like Larotrectinib or Entrectinib has shown a significant response rate exceeding 75%, irrespective of the specific histology of the tumour (Cocco et al. 2018). The gene discussed is NTRK1; the disease is neoplasm.